Combination Treatment of SGLT2 Inhibitors and GLP-1 Receptor Agonists: Symbiotic Effects on Metabolism and Cardiorenal Risk.
about
Combination Treatment of SGLT2 Inhibitors and GLP-1 Receptor Agonists: Symbiotic Effects on Metabolism and Cardiorenal Risk.
description
2018 nî lūn-bûn
@nan
2018年の論文
@ja
2018年学术文章
@wuu
2018年学术文章
@zh
2018年学术文章
@zh-cn
2018年学术文章
@zh-hans
2018年学术文章
@zh-my
2018年学术文章
@zh-sg
2018年學術文章
@yue
2018年學術文章
@zh-hant
name
Combination Treatment of SGLT2 ...... tabolism and Cardiorenal Risk.
@en
Combination Treatment of SGLT2 ...... tabolism and Cardiorenal Risk.
@nl
type
label
Combination Treatment of SGLT2 ...... tabolism and Cardiorenal Risk.
@en
Combination Treatment of SGLT2 ...... tabolism and Cardiorenal Risk.
@nl
prefLabel
Combination Treatment of SGLT2 ...... tabolism and Cardiorenal Risk.
@en
Combination Treatment of SGLT2 ...... tabolism and Cardiorenal Risk.
@nl
P2860
P1433
P1476
Combination Treatment of SGLT2 ...... etabolism and Cardiorenal Risk
@en
P2093
David S H Bell
P2860
P2888
P304
P356
10.1007/S13300-018-0420-6
P577
2018-04-05T00:00:00Z
P6179
1103182896